fezolinetant
Sign in to saveFezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, selective neurokinin-3 (NK3) receptor antagonist taken by mouth. It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.
Key facts
- Drug.image
- Fezolinetant.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.caption
- Above: molecular structure of fezolinetant Below: 3D representation of a fezolinetant molecule
- Drug.image2
- Fezolinetant 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Veozah, Veoza
- Drug.MedlinePlus
- a623051
- Drug.DailyMedID
- Fezolinetant
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- G02
- Drug.ATC_suffix
- CX06
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- <
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
~5 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- History
- Society and culture
- Legal status
- Brand names
- References
Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, selective neurokinin-3 (NK3) receptor antagonist taken by mouth. It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.
The most common side effects of fezolinetant include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.
Excerpted from Wikipedia’s “fezolinetant” article, available under the CC BY-SA 4.0 licence.